Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

York University

$25,000.00

Protein crystallization as a mechanism for biosimilar formulation

FY 2019-20

Summary
Apobiologix, a division of Apotex, is a market leader in the production and distribution of biosimilars. Biosimilars are complex biological molecules, such as proteins or antibodies, which are highly similar to other biological products already on the market. In order to bring a protein to market, it needs to be prepared and stabilized in a process known as formulation. In an effective formulation a protein is required to be at a high concentration, however this can lead to undesirable increases in viscosity, abnormal protein aggregation, precipitation, degradation, or loss in stability, all of which are undesirable. An alternate approach to increase a protein's concentration is through crystallization; protein crystals are semi-solid (unlike salt crystals), and therefore maintain a very large protein concentration without the drawbacks of simply adding more protein to the solution. However, crystallization of each molecule requires unique conditions that must be determined through an empirical investigation of screening and optimization prior to stabilization of the crystals for downstream formulation processes. Apobiologix does not have in-house expertise in protein crystallization, and has therefore partnered with York University to identify and optimize a framework for protein crystallization as a mechanism for biosimilar formulation. The research outlined in the current application seeks to determine a crystallization and stabilization framework for a recombinant human growth hormone (rhGH) biosimilar. Research will focus on identifying multiple crystallization conditions for rhGH that will then be optimized to scale, while ensuring the long term stability of the rhGH crystals in formulation solutions. Crystallized and stabilized rhGH can then be moved into the biosimilar product pipeline at Apobiologix, resulting in bringing this protein biosimilar to market. With the support of this proposal, we aim to (1) develop an on-going research partnership between Apobiologix and York University, and (2) foster future research into the crystallization of biosimilars for product development.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
539206-2019
Name nom
Audette, Gerald
Department département
Chemistry
Organization id
38
Institution établissement
York University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Protein crystallization as a mechanism for biosimilar formulation
Keyword
NSERC
Application summary
Apobiologix, a division of Apotex, is a market leader in the production and distribution of biosimilars. Biosimilars are complex biological molecules, such as proteins or antibodies, which are highly similar to other biological products already on the market. In order to bring a protein to market, it needs to be prepared and stabilized in a process known as formulation. In an effective formulation a protein is required to be at a high concentration, however this can lead to undesirable increases in viscosity, abnormal protein aggregation, precipitation, degradation, or loss in stability, all of which are undesirable. An alternate approach to increase a protein's concentration is through crystallization; protein crystals are semi-solid (unlike salt crystals), and therefore maintain a very large protein concentration without the drawbacks of simply adding more protein to the solution. However, crystallization of each molecule requires unique conditions that must be determined through an empirical investigation of screening and optimization prior to stabilization of the crystals for downstream formulation processes. Apobiologix does not have in-house expertise in protein crystallization, and has therefore partnered with York University to identify and optimize a framework for protein crystallization as a mechanism for biosimilar formulation. The research outlined in the current application seeks to determine a crystallization and stabilization framework for a recombinant human growth hormone (rhGH) biosimilar. Research will focus on identifying multiple crystallization conditions for rhGH that will then be optimized to scale, while ensuring the long term stability of the rhGH crystals in formulation solutions. Crystallized and stabilized rhGH can then be moved into the biosimilar product pipeline at Apobiologix, resulting in bringing this protein biosimilar to market. With the support of this proposal, we aim to (1) develop an on-going research partnership between Apobiologix and York University, and (2) foster future research into the crystallization of biosimilars for product development.